Lipoprotein (a) Testing in Patients With Atherosclerotic Cardiovascular Disease in 5 Large US Health Systems
Lipoprotein (a) testing in patients with atherosclerotic cardiovascular disease is infrequent, with evidence of disparities among older or Black individuals. Testing for lipoprotein (a), regardless of level, is associated with greater initiation of any lipid-lowering therapy, while elevated lipoprotein (a) is associated with greater initiation of nonstatin lipid-lowering therapy. There is a critical need for multidisciplinary and inclusive approaches to raise awareness for lipoprotein (a) testing, and its implications on management.
Authors
- Zachary Lampron
- Karen Chiswell (ORCID: https://orcid.org/0000-0002-0279-9093)
- Hillary Mulder (ORCID: https://orcid.org/0000-0003-4838-582X)
- Adrian F. Hernandez (ORCID: https://orcid.org/0000-0003-3387-9616)
- Lauren Cohen (ORCID: https://orcid.org/0000-0002-4597-7638)
- Manesh R. Patel (ORCID: https://orcid.org/0000-0002-2393-0855)
- Steven M. Bradley (ORCID: https://orcid.org/0000-0003-4006-6760)
- Susan Taubes
- Anum Saeed (ORCID: https://orcid.org/0000-0003-1783-678X)
- Daniel P. Morin (ORCID: https://orcid.org/0000-0002-9637-9507)
- Suresh Mulukutla (ORCID: https://orcid.org/0000-0001-5060-429X)
- Nishant Shah (ORCID: https://orcid.org/0000-0002-2666-7132)
- Elizabeth Lydon (ORCID: https://orcid.org/0009-0005-9487-8598)
- Xingdi Hu
- Neha Jadeja Pagidipati (ORCID: https://orcid.org/0000-0002-5004-8868)
- Wen‐Liang Song (ORCID: https://orcid.org/0000-0002-1866-0635)
Institutions
- Allina Health (US)
- University of Pittsburgh (US)
- Vanderbilt University (US)
- Ochsner Medical Center (US)
- Clinical Research Institute (US)
- Novartis (United States) (US)
- Duke University Hospital (US)
Publication Details
- Journal
- Journal of the American Heart Association
- Published
- 2024-11-04
- DOI
- https://doi.org/10.1161/jaha.124.035610
- Citations
- 15
- Primary Topic
- Lipoproteins and Cardiovascular Health
- Type
- article
- Field-Weighted Citation Impact
- 8.59